Scarica l'app Stockscreener
4.51
0.66%
-0.03
Dopo l'orario di chiusura:
4.51
Precedente Chiudi:
$4.54
Aprire:
$4.55
Volume 24 ore:
40,563
Relative Volume:
0.48
Capitalizzazione di mercato:
$45.30M
Reddito:
$1.15M
Utile/perdita netta:
$-46.90M
Rapporto P/E:
-0.8987
EPS:
-5.0182
Flusso di cassa netto:
$-42.37M
1 W Prestazione:
-9.80%
1M Prestazione:
-15.38%
6M Prestazione:
-45.53%
1 anno Prestazione:
-72.98%
Intervallo 1D:
$4.43
$4.62
Intervallo di 1 settimana:
$4.43
$4.94
Portata 52W:
$4.43
$29.98
Seres Therapeutics Inc Stock (MCRB) Company Profile
Nome
Seres Therapeutics Inc
Settore
Industria
Telefono
617 945 9626
Indirizzo
200 SIDNEY STREET, CAMBRIDGE, MA
Compare MCRB vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MCRB
Seres Therapeutics Inc
|
4.51 | 45.60M | 1.15M | -46.90M | -42.37M | -5.0182 |
VRTX
Vertex Pharmaceuticals Inc
|
515.57 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.86 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
986.80 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
211.94 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.66 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-08 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2024-10-24 | Downgrade | JP Morgan | Neutral → Underweight |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2023-04-21 | Iniziato | JP Morgan | Neutral |
| 2021-07-23 | Downgrade | Goldman | Neutral → Sell |
| 2021-05-18 | Ripresa | Goldman | Neutral |
| 2021-03-05 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2020-09-18 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2020-08-18 | Iniziato | Piper Sandler | Overweight |
| 2020-08-11 | Reiterato | H.C. Wainwright | Buy |
| 2020-08-11 | Aggiornamento | Jefferies | Hold → Buy |
| 2019-04-30 | Iniziato | Jefferies | Hold |
| 2018-10-22 | Iniziato | Chardan Capital Markets | Buy |
| 2017-10-13 | Iniziato | Oppenheimer | Outperform |
| 2017-08-04 | Reiterato | H.C. Wainwright | Buy |
| 2017-02-01 | Reiterato | FBR & Co. | Outperform |
| 2016-08-12 | Reiterato | FBR Capital | Outperform |
| 2016-08-01 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2016-08-01 | Reiterato | H.C. Wainwright | Buy |
| 2016-07-29 | Ripresa | H.C. Wainwright | Buy |
| 2016-03-30 | Iniziato | FBR Capital | Outperform |
| 2016-03-03 | Iniziato | Guggenheim | Buy |
| 2016-01-25 | Iniziato | H.C. Wainwright | Buy |
| 2015-10-22 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2015-07-22 | Iniziato | Canaccord Genuity | Buy |
| 2015-07-21 | Iniziato | Goldman | Neutral |
| 2015-07-21 | Iniziato | Leerink Partners | Outperform |
Mostra tutto
Seres Therapeutics Inc Borsa (MCRB) Ultime notizie
Seres Therapeutics, Inc. Revenue Breakdown – NASDAQ:MCRB - TradingView
Seres TherapeuticsMay Offer Up To $300 Million Of Securities - TradingView
MCRB Stock Declines As Seres Therapeutics Pauses SER-155 Phase 2 Study And Shrinks Headcount By 30% - Stocktwits
Seres Therapeutics Inc (MCRB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Seres Therapeutics exits more Cambridge real estate early - The Business Journals
Seres Therapeutics Inc earnings beat by $2.77, revenue topped estimates - Investing.com
Seres Therapeutics Q2 Operating Income USD -2 - Moomoo
Seres Therapeutics, Inc. 2Q 2026: Revenue $0.736M, Net income $4.581M, EPS $0.47— 10-Q Summary - TradingView
Seres Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Seres Therapeutics (MCRB) Q2 Revenue Surpasses Expectations Amid Clinical Progress - GuruFocus
Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs - The Manila Times
Seres Therapeutics Q2 Net Income Reaches $4.6 Million - Quiver Quantitative
Seres Therapeutics: Q2 Earnings Snapshot - marketscreener.com
Seres Therapeutics reports Q2 2026 net income of $4.6M, cash $15.6M, advances SER-155 clinical plans - TradingView
MCRB: Returned to profitability in Q2 2026, driven by VOWST sale gains and SER-155 trial success - TradingView
Q2 2026 financial results released as Seres Therapeutics advances business update - Traders Union
Seres Therapeutics Reports Second Quarter 2026 Financial - GlobeNewswire
Seres Therapeutics Streamlines Cambridge Operations with Lease Changes - TipRanks
MCRB Q2'26 Earnings: EPS estimate is (2.19) USD - TradingView
Seres Therapeutics Inc expected to post a loss of $2.18 a shareEarnings Preview - TradingView
MCRB Q2'26 Earnings: revenue estimate is 179.00K USD - TradingView
Seres Therapeutics Inc (MCRB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Seres Therapeutics Inc (MCRB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Seres Therapeutics (MCRB) Slides Slightly as Stock Tests Key Support LevelChange of Character - dars.gov.et
TradingKey - TradingKey
Seres Therapeutics Inc (MCRB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Seres Therapeutics Inc Revenue Breakdown – BX:MCRB - TradingView
Seres Therapeutics Inc (MCRB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
MCRB|Seres Therapeutics Inc|Price:4.980|Chg%:-0.250 - TradingKey
Seres Therapeutics Inc (MCRB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Seres Therapeutics (MCRB) H.C. Wainwright 4th Annual BioConnect Investor Conference summary - Quartr
Seres Therapeutics Slides 5.25% as MCRB Approaches Critical Support at $4.80Symmetrical Triangle - dars.gov.et
Seres Therapeutics (MCRB) Plunges 9%: Key Support and Resistance Levels in FocusIsland Reversal - dars.gov.et
Form 4 Seres Therapeutics Inc For: 10 July By Investing.com - Investing.com South Africa
Seres Therapeutics (MCRB) awards director Eric Shaff 6,500 stock options at $7.14 - Stock Titan
Seres Therapeutics (MCRB) awards 6,500-share stock option grant to director Dere - Stock Titan
[Form 4] Seres Therapeutics, Inc. Insider Trading Activity - Stock Titan
Seres Therapeutics (MCRB) awards 6,500 stock options to director Claire Fraser - Stock Titan
Seres Therapeutics (MCRB) awards 6,500 stock options to director Robert L. Rosiello - Stock Titan
Seres Therapeutics (MCRB) awards 6,500 stock options to director Stephen Berenson - Stock Titan
Seres Therapeutics’ SER-155 Posts 80% Response in Cancer Immunotherapy GI Toxicity Study - Yahoo Finance
Seres Therapeutics, Inc. Amends and Restates 2025 Incentive Award Plan in SEC 8-K Filing - Minichart
Seres Therapeutics Shareholders Approve Directors and Executive Pay - TipRanks
Seres Therapeutics (NASDAQ: MCRB) investors back 900,000-share 2025 incentive plan increase - Stock Titan
Seres Therapeutics (MCRB) Q4 2025 earnings summary - Quartr
Why Is Seres Therapeutics Stock Falling Today?Seres Therapeutics (NASDAQ:MCRB) - Benzinga
Seres Therapeutics, Inc. (MCRB) Discusses Promising SER-155 Clinical Trial Results for Immune Checkpoint Inhibitor Related AndropilatisSlideshow (NASDAQ:MCRB) 2026-07-08 - Seeking Alpha
Seres Therapeutics reports positive early SER-155 data - grafa.com
Seres’ SER-155 takes on immune checkpoint inhibitor-related enterocolitis - BioWorld News
MCRB: All proposals, including director elections and incentive plan amendment, were approved - TradingView
Seres reports trial results for experimental colitis treatment - Investing.com
Seres Therapeutics Inc Azioni (MCRB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Seres Therapeutics Inc Azioni (MCRB) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Shaff Eric D. | Director |
May 18 '26 |
Sale |
7.53 |
259 |
1,950 |
12,040 |
| DesRosier Thomas | See Remarks |
May 18 '26 |
Sale |
7.53 |
79 |
595 |
7,954 |
| Henn Matthew R | See Remarks |
May 18 '26 |
Sale |
7.53 |
77 |
580 |
7,838 |
| Brady Kelly | See Remarks |
May 18 '26 |
Sale |
7.53 |
59 |
444 |
8,562 |
2.20%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):